Evidence map›Paper›PMID 42130778›Full record

ArticlePsychedelic medicine (New Rochelle, N.Y.)2026

Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.

Pim B van der Meer, Nout Schukking, Maarten Dik, Aumer van Reemst, Juan J Fuentes, Ad A Kaptein, Jan W Schoones, Sebastiaan Verboeket, Marleen M de Waal, Anneke E Goudriaan and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychedelic medicine (New Rochelle, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pim B van der MeerDepartment of Neurology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0003-3700-8906
Nout SchukkingDepartment of Psychiatry, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Maarten DikDepartment of Psychiatry, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Aumer van ReemstDepartment of Psychiatry, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Juan J FuentesAddiction Program, Institute Salut Mental, Hospital del Mar, Barcelona, Spain.
Ad A KapteinDepartment of Medical Psychology, Leiden University Medical Center, Leiden, The Netherlands.
Jan W SchoonesDirectorate of Research Policy, Leiden University Medical Center, Leiden, The Netherlands.
Sebastiaan VerboeketDepartment of Research and Jellinek, Arkin Mental Health Care, Amsterdam, The Netherlands.
Marleen M de WaalDepartment of Research and Jellinek, Arkin Mental Health Care, Amsterdam, The Netherlands.
Anneke E GoudriaanDepartment of Research and Jellinek, Arkin Mental Health Care, Amsterdam, The Netherlands.
Cornelis KramersDepartment of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
Arnt SchellekensNijmegen Institute for Science Practitioners in Addiction (NISPA), Nijmegen, The Netherlands.
Matthijs G BossongBedrocan International B.V., Clinical Research Unit, Utrecht, The Netherlands.
Metten SomersDepartment of Psychiatry, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Albert BatallaDepartment of Psychiatry, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available evidence and identify potential research gaps. Methods: A systematic literature search was performed in eight different databases up to February 2024. Clinical trials were included that assessed the efficacy and safety of psychoactive tryptamines other than psilocybin and ibogaine. A quality assessment of the included trials was done based on the revised Cochrane risk-of-bias tools. Results: A total of four clinical trials (three randomized controlled trials and one single-arm clinical trial; Conclusion: Studies assessing the efficacy of psychoactive tryptamines other than psilocybin and ibogaine in addiction are scarce and show limited evidence for effectiveness in the treatment of addictive disorders.

Indexed as

drug addictionhallucinogenspsychedelicssubstance abusesubstance-related disorderstryptamines

Identifiers

PMID42130778
PMCPMC13089291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.